Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.723,50
0,00%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Inhibikase Therapeutics Inc (IKT) Inhibikase Therapeutics Inc (IKT) Notizie

IKT

Inhibikase Therapeutics (IKT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IKT
DataOraFonteTitoloSimboloCompagnia
22/05/202414:55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IKTInhibikase Therapeutics Inc
20/05/202414:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IKTInhibikase Therapeutics Inc
20/05/202414:01GlobeNewswire Inc.Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionNASDAQ:IKTInhibikase Therapeutics Inc
16/05/202402:00GlobeNewswire Inc.Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
15/05/202423:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IKTInhibikase Therapeutics Inc
15/05/202414:45GlobeNewswire Inc.Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementNASDAQ:IKTInhibikase Therapeutics Inc
15/05/202413:56Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:IKTInhibikase Therapeutics Inc
09/05/202420:41Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
09/05/202414:00GlobeNewswire Inc.Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
18/04/202422:30GlobeNewswire Inc.Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsNASDAQ:IKTInhibikase Therapeutics Inc
03/04/202414:05GlobeNewswire Inc.Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionNASDAQ:IKTInhibikase Therapeutics Inc
27/03/202421:15GlobeNewswire Inc.Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityNASDAQ:IKTInhibikase Therapeutics Inc
07/03/202414:30GlobeNewswire Inc.Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersNASDAQ:IKTInhibikase Therapeutics Inc
28/02/202422:05GlobeNewswire Inc.Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001ProNASDAQ:IKTInhibikase Therapeutics Inc
07/02/202413:55GlobeNewswire Inc.Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal CancersNASDAQ:IKTInhibikase Therapeutics Inc
29/01/202415:05GlobeNewswire Inc.Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with RisvodetinibNASDAQ:IKTInhibikase Therapeutics Inc
16/01/202422:05GlobeNewswire Inc.Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph FrattaroliNASDAQ:IKTInhibikase Therapeutics Inc
04/12/202314:35GlobeNewswire Inc.Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001ProNASDAQ:IKTInhibikase Therapeutics Inc
14/11/202322:30GlobeNewswire Inc.Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
07/11/202315:28GlobeNewswire Inc.Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023NASDAQ:IKTInhibikase Therapeutics Inc
07/11/202314:00GlobeNewswire Inc.Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023NASDAQ:IKTInhibikase Therapeutics Inc
16/10/202323:24Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:IKTInhibikase Therapeutics Inc
16/10/202313:00GlobeNewswire Inc.Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing EnrollmentNASDAQ:IKTInhibikase Therapeutics Inc
04/10/202314:30GlobeNewswire Inc.Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System AtrophyNASDAQ:IKTInhibikase Therapeutics Inc
24/08/202314:30PR Newswire (US)Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinibNASDAQ:IKTInhibikase Therapeutics Inc
22/08/202314:05PR Newswire (US)Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement DisordersNASDAQ:IKTInhibikase Therapeutics Inc
21/08/202314:30PR Newswire (US)Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinibNASDAQ:IKTInhibikase Therapeutics Inc
17/08/202314:30PR Newswire (US)Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001ProNASDAQ:IKTInhibikase Therapeutics Inc
14/08/202322:20PR Newswire (US)Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period ActivityNASDAQ:IKTInhibikase Therapeutics Inc
07/08/202314:05PR Newswire (US)Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023NASDAQ:IKTInhibikase Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IKT

La tua Cronologia

BOV
IFMILHO
IFMILHO
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network